EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy

Takanobu Iwadare, Takefumi Kimura iD, Ayumi Sugiura, Taiki Okumura, Shun-Ichi Wakabayashi, Hiroyuki Kobayashi, Yuki Yamashita, Tomoo Yamazaki, Satoru Joshita iD, Naoki Tanaka, Takeji Umemura iD

Journal of Viral Hepatitis · 2025

DOI: 10.1111/jvh.14025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Takanobu Iwadare und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Liver Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, The Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicentre study investigated the dynamics of thrombospondin 2 (TSP2) levels during direct‐acting antiviral (DAA) therapy in hepatitis C virus (HCV) infected patients and evaluated TSP2's potential as a predictive marker for hepatocellular carcinoma (HCC). All 134 participants achieved sustained virological response at 12 weeks (SVR12) with DAA therapy, and serum TSP2 levels significantly decreased from before and after treatment ( p < 0.001). During the median follow‐up period of 6.0 years, HCC after DAA therapy was observed in 16 patients (11.9%). Patients with serum TSP2 High (≥ 32 ng/mL) at SVR12 had a significantly higher cumulative occurrence of HCC than did those without (26.5% vs. 7.0%, p = 0.0033). A multivariate Cox proportional hazards model identified male gender (HR 4.84, p = 0.005), HCC history (HR 4.61, p = 0.017) and TSP2 High (HR 3.93, p = 0.009) as significant independent predictors of HCC occurrence after DAA therapy. The model had a high concordance index of 0.878. Additionally, combining TSP2 High and FIB‐4 High (≥ 3.538) at SVR12 yielded high specificity and negative predictive value (0.941 and 0.917, respectively) for predicting HCC. Kaplan–Meier analysis showed a higher HCC incidence in the TSP2 High + FIB‐4 High group (log‐rank p < 0.0001). In conclusion, TSP2 may be a promising biomarker for personalised HCC surveillance in DAA‐treated hepatitis C patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsCarcinoma, HepatocellularHepatitis C, ChronicLiver NeoplasmsThrombospondinsAdultAgedFemaleHumansMaleMiddle AgedBiomarkersLongitudinal StudiesPrognosisSustained Virologic ResponseThrombospondin 2

Stichwörter der Autor:innen

biomarkerdirect‐acting antiviralshepatitis C virushepatocellular carcinomathrombospondin 2

Substanzen

Antiviral AgentsBiomarkersThrombospondinsThrombospondin 2

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine, Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
  • Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto, Nagano, Japan.
  • Department of Internal Medicine, Sato Hospital, Nakano, Nagano, Japan.
  • Department of Medicine, University of California San Diego, La Jolla, California, USA.
  • Department of Internal Medicine, Yodakubo Hospital, Nagawa, Nagano, Japan.
  • Department of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto, Nagano, Japan.

ORCID-Profile: Takefumi Kimura, Satoru Joshita, Takeji Umemura

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • The Research Center for GLOBAL and LOCAL Infectious Diseases, Oita University

Zitieren

APA

Iwadare, T., Kimura, T., Sugiura, A., Okumura, T., Wakabayashi, S. I., Kobayashi, H., Yamashita, Y., Yamazaki, T., Joshita, S., Tanaka, N., & Umemura, T. (2025). Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.14025

Vancouver

Iwadare T, Kimura T, Sugiura A, Okumura T, Wakabayashi SI, Kobayashi H, et al. Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.14025

BibTeX
@article{Iwadare2025,
  author = {Iwadare, Takanobu and Kimura, Takefumi and Sugiura, Ayumi and Okumura, Taiki and Wakabayashi, Shun-Ichi and Kobayashi, Hiroyuki and Yamashita, Yuki and Yamazaki, Tomoo and Joshita, Satoru and Tanaka, Naoki and Umemura, Takeji},
  title = {Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy},
  journal = {Journal of Viral Hepatitis},
  year = {2025},
  doi = {10.1111/jvh.14025}
}
Kostenlos starten →